Press Release - December 1, 2022
Heidelberg, Germany, December 1, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host an investor event on December 10 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.
Date and Time: Saturday, December 10 at 4:00 p.m. CST / 5:00 p.m. EST / 23:00 CET
Location: New Orleans, LA and virtual
Affimed will host an investor event to review AFM13 clinical data and development plans in CD30 expressing malignancies. The investor event will take place in-person and virtually and a webcast of the event will be available in the “Webcasts” section on the “Investors” page of Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
To access the event via phone, please dial +1 (929) 205-6099 for U.S. callers, or +44 (203) 481-5240 for international callers, and reference meeting ID 847 4106 6227 approximately 15 minutes prior to the call.
A replay of the webcast/call will be archived on Affimed’s website for 30 days after the call.
AFM13 is a CD30/CD16A bispecific Innate Cell Engager (ICE®) that is investigated in Hodgkin Lymphoma (HL) and T cell lymphoma (TCL). AFM13 has shown single agent efficacy in HL and TCL and is currently being evaluated as monotherapy in a single arm registration-directed trial in peripheral TCL (REDIRECT). In addition, AFM13 showed high response rates in combination with the anti-PD-1 antibody Keytruda® (ORR: 88%, CR: 46%) and in combination with allogeneic cord blood-derived NK cells (ORR: 100%, CR: 71%). Affimed recently entered into a partnership with Artiva to develop AFM13 in combination with Artiva’s allogeneic, cryopreserved, NK cell product AB-101 in HL and TCL.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Director, Investor Relations
Tel.: +1 (917) 436-8102